Skip to main content
. 2020 Jul 10;12(13):13633–13646. doi: 10.18632/aging.103483

Figure 3.

Figure 3

Melatonin enhances proliferation on doxorubicin-treated CHRF cells and repairs G2/M cell cycle arrest induced by doxorubicin. (A) Relative cells proliferation treated by different concentration (10-9 M~10-7 M) of doxorubicin for 24 h. (B) Proliferation analysis of doxorubicin-treated CHRF cells with or without melatonin (200 nM) on days 0, 3, 6 and 9, (n=3). (C) Cell cycle analysis of doxorubicin-treated CHRF cells with or without melatonin (200 nM) for four days (n=4). (D) Cell cycle assessed by flow cytometry (n=4). (E) Cell apoptosis analysis of doxorubicin-treated CHRF cells with or without melatonin (200 nM) for, n=3. (F) Detection of Annexin V by flow cytometry, n=3. One-way ANOVA or Two-way ANOVA (with a Tukey multiple comparison test) was employed to test for significance. #Compared with control group, p< 0.05, # # p< 0.01; * compared with doxorubicin-treat group, p< 0.05, ** p< 0.01.